Dihexa vs Semax
Both Dihexa and Semax are used for cognitive and neuroprotection. Here's how their evidence, dosing, and regulatory status actually compare.
Dihexa
Evidence CDihexa (PNB-0408)
An angiotensin IV-derived hexapeptide that mimics hepatocyte growth factor (HGF)/c-Met signaling and produced rapid synaptogenesis in animal models. No human trials.
View full Dihexa profile →Semax
Evidence BSemax (MEHFPGP)
A synthetic ACTH fragment that increases BDNF levels and enhances focus, memory, and mental clarity. Delivered intranasally for rapid cognitive effects.
View full Semax profile →Side-by-Side
| Attribute | Dihexa | Semax |
|---|---|---|
| Evidence Grade | C | B |
| FDA Status | Not FDA-approved — research compound (HGF/c-Met-mimetic) | Not FDA-approved in US — approved in Russia for stroke and cognitive disorders |
| Typical Dose | 8–45 mg orally daily (research-only) | 200–600 mcg intranasal, morning |
| Clinics Indexed | 10 | 89 |
| Categories | cognitive, neuroprotection | cognitive, neuroprotection |
Key reported benefits — Dihexa
- ✓Synaptogenesis (preclinical)
- ✓Memory improvement (animal)
- ✓Possible Alzheimer's relevance
Key reported benefits — Semax
- ✓BDNF increase
- ✓Enhanced focus
- ✓Memory improvement
- ✓Neuroprotection
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.